Jubilant Pharmova Q2 FY26 Profit Rises By 21% YoY to ₹124 Crore; Revenue Up 12% At ₹1,966 crore

Noida, October 31, 2025: Jubilant Pharmova Limited (NSE: JUBLPHARMA) reported strong performance in the second quarter of FY26, led by growth across its Radiopharma, Allergy Immunotherapy, and CDMO Sterile Injectables businesses. The consolidated net profit rose by 21% YoY to ₹124 crore, while revenue climbed by 12% at ₹1,966 crore, reflecting continued operational momentum and improved margins.

Jubilant Pharmova Ltd., with its headquarters in Noida, is a diversified global pharmaceutical company with businesses in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, CRDMO, Generics, and Proprietary Novel Drugs. With six manufacturing sites and three R&D centers in North America, Europe, and India, the company has about 5,500 employees across the world and continues to focus on sustainable innovation and long-term value creation.

Stock Performance and Market Reaction

Despite the strong quarterly performance, the share price of Jubilant Pharmova traded marginally lower in Friday’s session, reflecting cautious investor sentiment. At 3:14 pm IST, the stock was down around 2.14% at ₹1,094.50. Analysts attributed the mild decline to profit booking and a slight rise in net debt due to ongoing expansion investments.

Financial Performance Overview

For Q2 FY26, total income stood at ₹1,976 crore, up 11% YoY. EBITDA rose 13% to ₹351 crore, with margins improving to 17.8% from 17.5% a year ago. Normalized PAT reached ₹124 crore, up 21% YoY, driven by higher sales in regulated markets and strong execution across key verticals.

For the first half of FY26, revenue grew 11% YoY to ₹3,867 crore, EBITDA rose 13% to ₹653 crore, and normalized PAT increased 32% to ₹227 crore, reflecting consistent earnings momentum.

Business Segment Highlights

The Radiopharma business posted a 16% YoY revenue increase to ₹291 crore, driven by higher Ruby-Fill® installations and expanding market adoption. The Allergy Immunotherapy segment grew 14% YoY to ₹194 crore, with EBITDA surging 65%, supported by robust demand in the US market.

The CDMO Sterile Injectables business recorded 30% YoY growth in revenue at ₹393 crore, driven by volumes from the third line at the Spokane facility. Margins were healthy despite the shutdown of operations at Montreal briefly due to quality upgrades.

CRDMO business saw steady increases, with Drug Discovery Services sales up 7% to ₹162 crore, and API segment up 8% to ₹137 crore. On its part, the Generics segment saw stable revenue at ₹167 crore, but profitability improved on the back of efficiency measures.

Strategic Updates and Outlook

The company has started generating revenue from Line 3 of its Spokane, US facility, with full commercial production expected by FY27. Line 4 is still on track for FY28, and the combined potential from these lines is expected at USD 160–180 million. Jubilant also completed its API business transfer to Jubilant Biosys Ltd, aimed at streamlining its operations and augmenting its CRDMO capabilities.

Net debt increased to ₹1,897 crore while maintaining a healthy leverage ratio at 1.5x EBITDA, reflecting planned growth investments.

Management Outlook

Chairman Shyam S. Bhartia and Co-Chairman Hari S. Bhartia said the quarterly results reaffirm the strategic direction and progress of the company in achieving its “Vision 2030” of doubling revenues to ₹13,500 crore, reaching 25% EBITDA margins, and becoming net-debt free by FY30.

REF: https://nsearchives.nseindia.com/corporate/JUBLPHARMA_31102025130944_Press_Release.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations